Introduction A translational bioinformatics challenge exists in connecting population and individual clinical phenotypes in various formats to biological mechanisms. The Medical Dictionary for Regulatory Activities (MedDRA Ò ) is the default dictionary for adverse event (AE) reporting in the US Food and Drug Administration Adverse Event Reporting System (FAERS). The ontology of adverse events (OAE) represents AEs as pathological processes occurring after drug exposures. Objectives The aim of this work was to establish a semantic framework to link biological mechanisms to phenotypes of AEs by combining OAE with MedDRA Ò in FAERS data analysis. We investigated the AEs associated with tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) targeting tyrosine kinases. The five selected TKIs/mAbs (i.e., dasatinib, imatinib, lapatinib, cetuximab, and trastuzumab) are known to induce impaired ventricular function (non-QT) cardiotoxicity.
is the default dictionary for adverse event (AE) reporting in the US Food and Drug Administration Adverse Event Reporting System (FAERS). The ontology of adverse events (OAE) represents AEs as pathological processes occurring after drug exposures. Objectives The aim of this work was to establish a semantic framework to link biological mechanisms to phenotypes of AEs by combining OAE with MedDRA Ò in FAERS data analysis. We investigated the AEs associated with tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) targeting tyrosine kinases. The five selected TKIs/mAbs (i.e., dasatinib, imatinib, lapatinib, cetuximab, and trastuzumab) are known to induce impaired ventricular function (non-QT) cardiotoxicity.
Results

Statistical analysis of FAERS data identified 1053 distinct MedDRA
Ò terms significantly associated with TKIs/mAbs, where 884 did not have corresponding OAE terms. We manually annotated these terms, added them to OAE by the standard OAE development strategy, and mapped them to MedDRA Ò . The data integration to provide insights into molecular mechanisms of drug-associated AEs was performed by including linkages in OAE for all related AE terms to MedDRA Ò and the existing ontologies, including the human phenotype ontology (HP), Uber anatomy ontology (UBERON), and gene ontology (GO). Sixteen AEs were shared by all five TKIs/mAbs, and each of 17 cardiotoxicity AEs was associated with at least one TKI/mAb. As an example, we analyzed ''cardiac failure'' using the relations established in OAE with other ontologies and demonstrated that one of the biological processes associated with cardiac failure maps to the genes associated with heart contraction. Conclusion By expanding the existing OAE ontological design, our TKI use case demonstrated that the combination of OAE and MedDRA Ò provides a semantic framework to link clinical phenotypes of adverse drug events to biological mechanisms.
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Key Messages
The ontology of adverse events (OAE) was extended with 884 additional clinical adverse event (AE) terms and correspondingly mapped to Medical Dictionary for Regulatory Activities (MedDRA Ò ) terms to classify AEs identified from the US Food and Drug Administration Adverse Event Reporting System (FAERS) data analysis of tyrosine kinase inhibitor (TKI) and monoclonal antibody (mAb)-associated AEs.
The OAE-based linkages found potentially useful relations between TKI/mAb AEs and biological processes.
The combination of MedDRA Ò and OAE in the TKI study provided the first use case of a semantic framework for linking clinical drug-AE phenotypes to biological processes and mechanisms.
Introduction
Advances in systems pharmacology have presented a growing challenge and opportunity to utilize complex bioinformatics and systems biology methods for pharmacovigilance research. The solution requires the development of an ontology-based framework that describes clinical (adverse drug) events and that goes beyond a simple classification of adverse events (AEs) [1] . The Medical Dictionary for Regulatory Activities (MedDRA Ò ) is used in standard AE reporting in the USA, Europe, and Japan [2] . The usage of MedDRA Ò has greatly facilitated AE report standardization and cross-report data analysis. There are a number of other ontologies and standard vocabularies that attempt to capture clinical phenotypes for AEs and clinical disease, including the mammalian phenotype ontology (MP) [3] , Systematized Nomenclature of Medicine-Clinical Term (SNOMED-CT) [4] , International Classification of Diseases (ICD) [5] , and Common Terminology Criteria for Adverse Events (CTCAE) [6, 7] . However, MedDRA Ò and the other data structures do not provide links to other information needed to explore and understand biological mechanisms associated with the AEs.
The ontology of adverse events (OAE)-previously known as adverse event ontology (AEO) [8, 9] -is a community-based, open-source ontology that supports the representation and analysis of clinical AE phenotypes [10] . In OAE, an AE is considered a pathological bodily process-a class defined as an occurrent in the basic formal ontology (BFO) [11] -and is described as an unpleasant or unexpected clinical phenotype that occurs after a medical treatment. This results in an ontological definition of the phenotype that differs from other ontologies describing phenotypes or disorders as a disposition (BFO's continuant [11] ), such as those of the human phenotype ontology (HP) [11, 12] , mammalian phenotype ontology (MP) [13] , human disease ontology (DOID) [14] , ontology for general medical sciences (OGMS) [15] , or experimental factor ontology [16] . OAE captures other related componentssuch as a medical intervention (e.g. drug exposure)-that are temporally associated with the occurrence of an AE. An adverse drug event is defined as a pathological bodily process that is preceded by a drug exposure. An AE may also resemble a disease process, but it needs to be defined and distinguished from a normal biological process. However, it is important to note that this temporal association does not imply causation.
The application of OAE has been previously demonstrated in a bioinformatics analysis of influenza vaccine AEs [17] , temporal analysis of vaccine AEs [18] , representation of genetic susceptibility to vaccine AEs [19] , and ontological representation of licensed vaccine AEs recorded in US Food and Drug Administration (FDA) drug label documents [20] .
The OAE class organization links an AE to a biological process or processes potentially associated with the AE, and the biological process can be further linked to other contents such as the anatomical location of the adverse process. Therefore, OAE semantically captures the relationships of AEs to the medical intervention leading to the occurrence of AEs and provides a possible framework to link clinically reported drug AEs to the underlying mechanisms [10] . The expansion and further development of OAE described here allows it to be used to explore mechanisms of drug-associated AEs as defined by MedDRA Ò terms. It is necessary to use the MedDRA Ò dictionary because it is the standard terminology for AE reporting. However, there has not been a clear and specific use case published to demonstrate the feasibility of such a framework for linking clinically reported MedDRA Ò AE terms to biological mechanisms of clinical phenotypes.
This study aimed to demonstrate the use of the ontological framework provided by OAE to link and hypothesize the linkage of MedDRA Ò -coded clinical phenotypes to underlying biological mechanisms. Our use case explored a drug exposure-AE pair: impaired contractility cardiotoxicity associated with inhibition of tyrosine kinases by tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs). Although TKIs and mAbs have slightly different mechanisms of action, both work to inhibit downstream activities in the tyrosine kinase signaling cascade. mAbs compete with ligand-binding dimerization at the membrane receptor, while TKIs block adenosine triphosphate (ATP) from binding to the intracellular tyrosine kinase domain, preventing its phosphorylation and leading to a non-activated tyrosine kinase cascade (in the case of TKIs) [21] . We selected five drugs from these two classes for this study: dasatinib, imatinib, lapatinib, cetuximab, and trastuzumab. All five drugs are loosely bundled and referred to as TKIs/mAbs in this study.
Methods
In this study, we expanded the existing OAE to include TKI-associated AEs. We focused our studies on five TKIs/ mAbs-dasatinib, imatinib, lapatinib, cetuximab, and trastuzumab-because these agents are associated with a high frequency of cardiotoxicity-related AEs [21] [22] [23] . The FDA Adverse Event Reporting System (FAERS) was mined on the basis of these five TKIs/mAbs. Currently, there are over 3900 MedDRA Ò terms in use in the FAERS database. AE terms of interest were normalized to conform to ontology construction guidelines. This permitted implementation with a formal representation having a proper definition, synonyms, cross-reference to MedDRA Ò and other reference terminologies, and relationships to other knowledge components such as the anatomical site and pathological process. This step included both cardiotoxic and non-cardiotoxic AEs, as the drug may induce AEs other than those related to the heart. A diagram summarizing this process is shown in Fig. 1 .
In the TKI queries in FAERS, AE terms for each drug were selected for the OAE-MedDRA Ò mapping process on the basis of a proportional reporting ratio (PRR) score of 2.0 and a minimum of three reports when the total number of reports was smaller than 1500, or 2 in 1000 cases (0.2 %) when the total number of reports was larger than 1500 [17] . These thresholds were selected to distinguish between a true AE signal and background noise on the basis of the FDA's experience with AE signal detection. A PRR of 2.0 implies that the AE was observed for a given drug-AE pair twice as frequently as was observed for the AE in the background comprised of all FAERS reports included in the analysis. The FAERS data are a heterogeneous collection of reports from clinical experts, consumers, and manufacturers. Therefore, this screening process is necessary to the study to identify the ''true'' signal from the background noise.
AEs reported in FAERS are coded by MedDRA Ò terminology. When the result of mining FAERS with TKI queries was an AE term that corresponded to an existing OAE class but the OAE class was previously missing a cross-reference to MedDRA Ò , we added the cross-reference of that MedDRA Ò term to the particular OAE class.
When the AEs mined from FAERS did not previously exist in OAE, the new AE terms were added to OAE along with the MedDRA Ò cross-reference information. For this study, data mining was performed on the public FAERS dataset available as of April 2013.
Following the addition of the TKI-associated cardiac AE terms to OAE, we manually curated their classification and ontological relationship among the classes in OAE to ensure the accuracy of data representation. We recruited the help of clinicians with expertise in cardiotoxicity to determine the proper classification of terms before they were inserted into the ontology structure. A complete description of the methods is given in a previously published work by He et al. [10] .
Data Clean-Up and Term Insertion
For each term that was prioritized by the rules set above, the reference definition used in the ontology was taken from a medical dictionary or terminology resources available from the National Library of Medicine (NLM) MedlinePlus
. The definition was the driver for assigning the proper classification for the term on the basis of the descriptor that could be linked to a pathophysiological process (e.g. edema, inflammation), with the anatomical location of the AE used as a secondary classification. This is a technique called axiomatization in ontology practice. For example, cardiac failure congestive AE is asserted as a subclass of cardiac failure AE via the is_a (SubClassOf) relation. This is the primary classification by the pathological process of congestive heart failure. At the same time, axiomatization places cardiac failure congestive AE as having the manifestation site as the heart via the axiom occurs_in the heart by inheriting from the cardiac disorder AE parent. Crossreferences to MedDRA:10007559, HP:0001635, and SIDER:C0018802 are also annotated to cardiac failure congestive AE as described in Fig. 2 . Having this infrastructure also allows for consolidation of the related clinical observations that are often used interchangeably by the clinicians. For example, cardiomyopathy is used to indicate the cause of a heart failure observation, while in relational terms cardiomyopathy links to congestive heart failure via the intermediate term of cardiomegaly. Clearly separating these terms by an ontology mechanism helps identify the associated biological process that underlies the heart failure occurrence as demonstrated in Fig. 2 . Linking out to the permanent URL (PURL) for each cross-reference resource can be implemented with minimal scripting, as the crossreference annotation in OAE conforms to the open biological and biomedical ontologies (OBO)-dbXref annotation recommendation.
In this OAE TKI-AE expansion process, the AE terms were manually examined by clinical experts for their Linking MedDRA Ò -Coded Clinical Phenotypes to Biological Mechanismsbiological and pathological relevance, and synonyms were identified to ensure the AE term was represented with the multiple alternative terms that are commonly used in clinical settings [e.g. cardiac failure congestive AE is also annotated with the alternative terms congestive heart failure and congestive cardiac failure, which are more common in practice despite the preferred label cardiac failure congestive in MedDRA Ò (Fig. 2) ]. These synonyms were captured with each AE class with the ontology standard annotation property alternative_term. The prepared terms were then verified for data completeness and the proper location in the ontology hierarchical arrangement (asserted classification). Cross-references of the source definition were recorded with the annotation property definition source. Information on the term editor, editor's note, and other related metadata details were also recorded in the term's annotation properties. Other annotation, data, or object properties that were not OAE specific were described with concepts inherited from upper-level ontologies that mandate OAE's ontology structure based on the OBO Foundry ontology development principles [25] .
An AE term is a subclass of the overarching class adverse event. The primary classification favors the biological and pathological process over the anatomical organs and tissues. Because the clinical manifestation may differ depending on the anatomical location that is primarily affected (e.g., mitochondrial toxicity manifests as pancreatitis in some cases, hepatotoxicity in others, and cardiotoxicity in yet others), the anatomical location is used as a secondary classifier, for which the classification hierarchy can be constructed (i.e. inferred) via the ontology reasoning mechanism, and therefore classification by organ system is also captured with OAE. Each AE class contains a reference to its corresponding MedDRA Ò number via the seeAlso annotation property. When applicable, reference was made to the corresponding HP uniform resource identifiers (URIs) [3] and/or MP URIs [13] and annotated with a seeAlso annotation property.
New AE terms that were not previously in OAE were manually defined and structurally aligned to OAE via the software program Ontorat (http://ontorat.hegroup.org) [26] . Ontorat programmatically constructs and defines relationships of the newly created AE classes by writing ontology syntax codes (axioms) to connect and align with the structure of OAE. Final consistency checking and adjustment of the overall output were done using Protégé version 4.2 (http://protege.stanford.edu/).
Adverse Event Classification and Analysis
Different subgroups of AEs were classified by obtaining the terms and the related hierarchical terms and relations from OAE using the OntoFox tool [27] . The additional TKI-related AEs not previously in OAE were merged into Fig. 1 Summary process diagram of curating the existing ontology of adverse events (OAE) with additional tyrosine kinase inhibitor (TKI)-association adverse event (AE) knowledge. The previously existing OAE was further expanded with the novel 884 terms. These terms were statistically significant by the proportional reporting ratio (PRR) score and the cut-off threshold (PRR C 2, N C 3). Each term was manually curated by clinician experts before it was placed at an appropriate hierarchical location inside OAE, along with the crossreferences to related information such as the Medical Dictionary for Regulatory Activities (MedDRA Ò ) and the anatomical location. OAE was then used to classified TKI-associated AEs and linked to biological processes in other ontologies such as the gene ontology and via the organ systems. FAERS US food and drug administration (FDA) adverse event reporting system, HP/MP human phenotype ontology/mammalian phenotype ontology, UBERON Uber anatomy ontology OAE in an ontology web language (OWL) format [28] , an ontology standard file that uses the eXtensible Markup Language (XML) syntax for interoperability across different computer operating platforms. The individual AE classes in the resulting OAE expansion were visualized in the Protégé-OWL editor and manually verified by clinical scientists familiar with drug-AE terminology.
Results
Mining the FAERS database with the five TKIs/mAbs resulted in a list of 1053 distinct AE terms. Of these terms, 126 were already in OAE prior to this investigation. After excluding ambiguous and non-AE terms, such as medical procedures, we identified 844 new terms to insert into OAE as newly created classes. A spreadsheet of all new terms was created as a common platform for collaboration between the informatics and clinical experts. The manual process of mining for the appropriate definitions of all 844 AEs (as described in the Sect. 2), along with the candidate information of the parent term and the anatomical manifestation site, was conducted by predoctoral individuals with expertise in pharmacology and engineering. The spreadsheet was reviewed by a clinical pharmacologist and a clinical toxicologist at the FDA Office of Clinical Pharmacology to verify the accuracy of the information. These terms were then added to OAE by an ontologist. Although the manual process was labor intensive, it was necessary to provide the required accuracy for the ontology. This manual step took approximately 1 month to complete all 844 AE terms. Additional information about organs/tissues and MedDRA Ò terms led to adjustments in such attributes in some of the existing terms, such as the anatomical entity, MedDRA Ò ID, refined definition, and references from the original OAE design pattern (Fig. 3) . The information allowed modification of the knowledge to further improve the clinical accuracy of OAE, as this TKI-based study mined the information from a much more informative resource (FAERS) than other sources without clinical relevance (e.g., listings from general medical vocabularies). This adjustment of the details may have changed some of the knowledge specific to certain terms in OAE but did not affect the original hierarchy of OAE or the logical design patterns (the axiomatization framework) of the ontology (i.e., the design pattern as depicted in Fig. 3 remained unchanged) . OAE is accessible Fig. 2 Example of using the ontology of adverse events (OAE) as a structured semantic framework to link the clinical observation cardiac failure congestive adverse event (AE) as a drug-associated AE to the underpinning biological relevance by the ontological crossreference mechanism linking an AE to a phenotypic abnormality described in the human phenotype ontology (HP). HP describes congestive heart failure as a phenotypic abnormality without any assumptions on what triggers such an observation. Combining knowledge in OAE with HP provides a seamless transition in linking a clinical observation (an AE) to biological processes and relevant human genes in the gene ontology (GO) via HP connection. [29] is the default linked data server for OAE. The OAE project homepage is located at http://www.oae-ontology. org/. A summary of OAE statistics is provided in Table 1 . The current OAE revision dated December 18, 2015, contains 5274 terms, including 5109 classes, 156 object properties, and 96 annotation properties (Table 1) .
OAE Design Pattern Accommodates Annotation of Clinical Adverse Drug Reactions
The OAE expansion in this study captures the cardiotoxicity AEs associated with TKIs/mAbs. The data analysis model is demonstrated in Fig. 4a , with an example of imatinib-associated pleural effusion AE as a child of edema AE shown in Fig. 4b . In this example, imatinib (an anticancer TKI) is administered orally and is described by the ontological relation occurs_in (i.e., a drug exposure occurs in the location of a route of administration) inherited from the BFO relation [30] . Components of the clinical, experimental, and biological processes were imported from the following existing resources: the gene ontology (GO) [31] , ontology for biomedical investigation (OBI) [32] , phenotypic quality ontology (PATO) [33] , mammalian phenotype ontology (MP) [13] , human phenotype ontology (HP) [3] , information artifact ontology (IAO) [34] , ontology for general medical sciences (OGMS) [15] , Uber anatomy ontology (UBERON) [35] , human disease ontology (DOID) [14] , and vaccine ontology (VO) [36, 37] . A summary of the imported classes is provided in Table 1 .
Cross-referencing with interoperable ontologies, as defined in the OBO Foundry documentation, allows linkages from the OAE-defined AE class to other resources by importing appropriate terms and mapping them to those resources. An AE occurs after a drug exposure (exist_at time T2) and therefore is_preceded_by a drug exposure that occurs at a specific time during the treatment (exist_at time T1). The drug exposure is described through the use of class planned_process, which is a concept imported from OBI. Therefore, the relationship between a reported AE and a preceding medical intervention is now established by the OAE information model. This aspect of temporal association between a treatment and its post-treatment AE differentiates OAE from other phenotype ontologies.
An AE is a subclass of the OGMS pathological bodily process. The AE hierarchy is then formed by an is_a (SubClassOf) relation that specifies a parent-child class term relation. This is an ontological relation that describes a specific AE as a type of AE associated with the drug exposure without implying a causal association. The association between an AE and the corresponding anatomical entity is specified by an occurs_in relation. This description of OAE is encoded in the OWL format, which can be coded for computational operations. The OAE.owl file is available for download on the project website, http://www.oae-ontology.org/. 
Classification of MedDRA
MedDRA
Ò -coded AE terms, as taken from FAERS for each TKI, were normalized and grouped into the OAE Fig. 3 Ontology of adverse events (OAE) hierarchy of adverse events (AEs), which facilitates the linkage of externally imported classes (blue) and OAE-specific classes (yellow). The OAE hierarchy is governed by the upper-level classes, which are imported from the basic formal ontology (BFO), ontology for general medical sciences (OGMS), and ontology for biomedical investigation (OBI), while the utility classes of the anatomical location that an AE is associated with are imported from the Uber anatomy ontology (UBERON) hierarchy. We also performed an intersection analysis of the AEs across the five TKIs/mAbs. There were 16 AE terms (counting at leaf nodes) that were common to all five TKIs/mAbs (Fig. 5a ), mostly involving homeostasis and inflammation responses (fever, pleural effusion, decreased blood granulocytes and potassium). One should note that cancer progression is also coded with MedDRA Ò AE association of interest for this study, 17 cardiotoxicity AE terms were used in querying FAERS data (Fig. 5b) . Each of these was associated with at least one of the five TKIs/mAbs and were the following 17 terms: cardiac function test abnormal, congestive cardiomyopathy, cardiovascular disorder, hypertrophic obstructive cardiomyopathy, cardiotoxicity, cardiac disorder, heart injury, ischemic cardiomyopathy, hypertrophic cardiomyopathy, myocardial rupture, hypertensive cardiomyopathy, restrictive cardiomyopathy, multiple cardiac defects, viral cardiomyopathy, non-obstructive cardiomyopathy, hypertension, and hypotension. The OAE subset shown in Fig. 5b lays out the relations among these AE terms and other related AE terms. The difference in the number of AEs reported for each TKI is not to be interpreted that one drug is safer than the others. This is in part a function of the Fig. 4 Ontology of adverse events (OAE) class design for representing an adverse event (AE). a Detailed OAE class structure of an AE as a subtype of another AE. The design pattern describes roles and interactions from a clinical perspective. b Example of the information on a pleural effusion AE described by the OAE basic design pattern in association with imatinib treatment Table 1 Current description of ontology of adverse events (OAE)-specific and imported terms. OAE includes 3229 terms whose term IDs start with the ''OAE_'' prefix. These OAE-specific terms include medical interventions, adverse event (AE) terms, and eight ontological relations describing activities associated with an AE (e.g., is_evidence_of). Many related ontology terms that have been defined in other existing biomedical ontologies are imported from correspondent ontologies as shown in the Linking MedDRA Ò -Coded Clinical Phenotypes to Biological Mechanismsduration for which the drug has been approved and available for use, resulting in different time periods of reporting for different TKIs/mAbs. We further performed a concept mapping by linkage to other ontologies to expand the network of knowledge to include other relevant information as exemplified in Fig. 6 with myocardial infarction AE and arteriosclerosis coronary AE. The diagram shows how an AE (a clinical observation) can be linked to biological systems and the anatomical location (often not explicitly stated in a patient's record). In this figure, the concept mapping diagram shows that an AE is a subclass of its parent AE class by the pathological process. It is associated with an anatomical system (UBERON) identified by an occurs_in relation. The pathological bodily process is referenced to GO biological process necrosis (which further links up to cell death activity by the GO-defined structure). Therefore, myocardial infarction AE is_a cardiac disorder AE, while arteriosclerosis coronary artery AE is_a arterial disorder AE. However, both cardiac disorder AE and arterial disorder AE are differentiated from the common parent class cardiovascular disorder AE. An OAE relation is_evidence_of has linked myocardial infarction as an AE that occurs in the myocardium to the arteriosclerosis coronary artery AE. Similar to the usage of the evidence ontology (ECO) [38] , the is_evidence_of relation is used to link back an AE as evidence to the original question. Ontology linkage of the AEs associated with TKIs/mAbs yields the network of knowledge of biological response that can be mapped back to different levels of biological organization, as illustrated in Figs. 2 and 6.
Use Case: Identification of Biological Processes/
Genes Involved in Cardiac Failure AE As a use case for OAE, we examined whether the links introduced in OAE to other ontologies would allow identification of biological processes and genes that contribute to cardiac AEs. We focused on cardiac failure AE as a use case (Fig. 2) . In OAE, cardiac failure AE is linked to HP with a seeAlso annotation property to HP:0001635 (congestive heart failure). Within HP, HP:0001635 is given a class relation where it is defined as ''Equivalent to: has_-part some (decreased amount and inheres_in some heart contraction and has_modifier some abnormal)''. ''Heart contraction'' is a biological process in GO (GO:0060047) ; however, after ontology reasoning, these two AE terms and their child terms are inferred under ''cardiovascular AE''. OntoFox was used to generate these OAE subset files, and the Protégé ontology web language (OWL) editor was used for the visualization and allows the information in HP to be linked to 2861 genes with GO's direct annotations of heart contraction. These annotations were done at the source database by manual curations (see the Electronic Supplementary Material file named GO_annotation_CongestiveHeartFail-ure.xlsx). Of the 2861 GO annotations, there are 190 unique Homo sapiens genes that are associated with heart contraction and could potentially have a role in cardiac failure (see the Electronic Supplementary Material file named GO_HSgenes_heartContractions.xlsx). Therefore, using OAE and the relationships to other ontologies defined for each term in OAE, we were able to link the clinical phenotype to the biological processes and genes that contribute to that phenotype.
Discussion
The major contributions of this paper are as follows: The process for addition of more than 800 AE terms to OAE provides a framework for further extension of OAE for better coverage in translational health research. Fig. 6 Concept mapping diagram. An adverse event (AE) is a subclass of (defined with an is_a relation) a parent AE by its pathological process and is associated with an anatomical location, which is linked to the Uber anatomy ontology (UBERON) by the ontology relation occurs_in. The pathological process is mapped to the corresponding gene ontology (GO) biological process via the is_evidence_of relation. Knowledge integration can be drawn from the concept mapping without having to put all relevant information into a single compilation. In this example, myocardial infarction AE is classified as a type of cardiac disorder AE, while arteriosclerosis coronary artery AE is a type of arterial disorder AE. Both cardiac disorder AE and arterial disorder AE are differentiated from cardiovascular disorder AE. Myocardial infarction AE as evidence of arteriosclerosis coronary artery AE is connected via an is_evidence_of relation. The occurs_in relation has specified myocardial infarction as an AE that occurs in the myocardium in the heart. These ontological relations provide a standardized data infrastructure to create linkage of knowledge among different standard ontologies Linking MedDRA Ò -Coded Clinical Phenotypes to Biological MechanismsSelection of new terms to be created in OAE has been done on a case-study basis, as there are over 36,000 terms in MedDRA Ò , and not every term is used with the same frequency for coding AEs. Manually refining all MedDRA Ò terms into an ontological infrastructure at once is not feasible for this reason. The selection of terms, however, does not introduce bias into the knowledge representation model inside OAE, as the value of this approach lies in the logical skeleton of the ontology itself, and not which data are represented. The manual examination of these terms, along with the PRR signal analysis, ensures that the biological relevance of an AE clinical observation is properly kept in the ontological format. To better serve various case studies, in the near future we plan to add all corresponding MedDRA Ò concepts that are frequently used in FAERS to OAE.
Although this study aimed to analyze the cardiotoxic AEs, the 3320 native OAE classes represent observations in several system organ parts outside the heart. This is because [1] OAE AEs are a collective set of studies; and [2] TKI/mAb-associated non-cardiotoxic AEs can be observed with cardiotoxic AEs. In our future work, it will be interesting to compare the cluster of the AE terms based on the MedDRA Ò System Organ Class (SOC) with the cluster of AE terms classified by occurs_in axioms within OAE. We would expect the result to be quite similar in the anatomy classification, as OAE is continually curated and axiomatized on the basis of the incoming knowledge. The speculated difference lies in the area of when an AE resides in multiple SOCs (such as an inflammation in an organ that can be classified in both a physiological location [e.g., the skin, eye, lung] and a pathological location [e.g., the immune system]). Ontological axiomatization of these biological activities will be more robust and computationally consistent than classification in a traditional treestructure listing of multiple parents achieved before the concept of biomedical ontology was introduced into the field.
Conclusions
Ontology development is an ongoing effort, especially in the domain of biomedical research, where new knowledge generation is continuous. OAE is designed to accommodate this continuous evolution of information and its interpretation. The ontology is built and expanded on a case-bycase basis. The expansion of OAE with TKI/mAb-associated AEs is a result of this process [9, 10, 17] . With the focus on TKI/mAb-associated AEs, we successfully added 844 new AE terms to OAE, most of which are cardiovascular disorder AEs or related terms. The AE terms were cross-referenced with MedDRA Ò and other reference vocabularies or ontologies (Medical Subject Headings [MeSH], SNOMED-CT, HP, or MP). They were carefully examined by clinicians to ensure proper classification, term definitions, and ontology relations to other terms within OAE. Reasoning with the knowledge embedded within OAE via axiomatization of logical rules based on the pathological process, the anatomical location of AE manifestation sites, and the medical intervention that precedes the occurrence of an AE may make the elucidation of molecular mechanisms associated with clinical drug AEs more efficient.
